康方生物(9926.HK)：临床突破不断全球潜力彰显

华泰证券00:00

依沃西单抗在多个临床结果中展现了显著的治疗获益，尤其在HARMONi-2研究中头对头击败帕博利珠单抗，展现了全球重磅潜力。我们预计未来依沃西单抗的海外探索将持续提升其收入峰值和公司估值。维持“买入”。临床结果：全方位击败帕博利珠单抗，早期临床验证多适应症潜力HARMONi-2 研究中，依沃西单抗头对头击败帕博利珠单抗，且数据优势明显：1）PFS 显著优于对照组（11.14 vs 5.82 月，HR...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492163114?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-19 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2492163114","market":"hk","top_or_hot":-1,"title":"康方生物(9926.HK)：临床突破不断 全球潜力彰显","media":"华泰证券","content":"<div>\n<p>依沃西单抗在多个临床结果中展现了显著的治疗获益，尤其在HARMONi-2研究中头对头击败帕博利珠单抗，展现了全球重磅潜力。我们预计未来依沃西单抗的海外探索将持续提升其收入峰值和公司估值。维持“买入”。临床结果：全方位击败帕博利珠单抗，早期临床验证多适应症潜力HARMONi-2 研究中，依沃西单抗头对头击败帕博利珠单抗，且数据优势明显：1）PFS 显著优于对照组（11.14 vs 5.82 月，HR...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219144711a1fa7aa2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物(9926.HK)：临床突破不断 全球潜力彰显</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物(9926.HK)：临床突破不断 全球潜力彰显\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219144711a1fa7aa2&s=b><strong>华泰证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>依沃西单抗在多个临床结果中展现了显著的治疗获益，尤其在HARMONi-2研究中头对头击败帕博利珠单抗，展现了全球重磅潜力。我们预计未来依沃西单抗的海外探索将持续提升其收入峰值和公司估值。维持“买入”。临床结果：全方位击败帕博利珠单抗，早期临床验证多适应症潜力HARMONi-2 研究中，依沃西单抗头对头击败帕博利珠单抗，且数据优势明显：1）PFS 显著优于对照组（11.14 vs 5.82 月，HR...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219144711a1fa7aa2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219144711a1fa7aa2&s=b","article_id":"2492163114","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219144711a1fa7aa2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2492163114","pubTimestamp":1734537600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"依沃西单抗在多个临床结果中展现了显著的治疗获益，尤其在HARMONi-2研究中头对头击败帕博利珠单抗，展现了全球重磅潜力。此外，依沃西单抗在NSCLC 围术期、头颈鳞癌、结直肠癌、TNBC 等II 期临床中展现良好疗效。此外，考虑到其他IO 联用抗血管生成的探索和依沃西单抗在部分瘤种的早期临床疗效，我们预计其适应症拓展将在海外展开，助推本品成为全球重磅级别品种。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09926":"康方生物","LU1720050803.USD":"安联全方位中国股票基金","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1161":"生物科技","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1574":"生物医药B类股","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"Akeso Biotech (9926. HK): Clinical breakthroughs continue to demonstrate global potential","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"依沃西单抗在多个临床结果中展现了显著的治疗获益，尤其在HARMONi-2研究中头对头击败帕博利珠单抗，展现了全球重磅潜力。我们预计未来依沃西单抗的海外探索将持续提升其收入峰值和公司估值。维持“买入”。临床结果：全方位击败帕博利珠单抗，早期临床验证多适应症潜力HARMONi-2 研究中，依沃西单抗头对头击败帕博利珠单抗，且数据优势明显：1）PFS 显著优于对照组（11.14 vs 5.82 月，HR=0.51）；2）各亚组均显著获益；3）安全性出众，停药和致死TRAE 发生率低（1.5%和0.5%），鳞癌患者无任何3 级出血事件。此外，依沃西单抗在NSCLC 围术期、头颈鳞癌、结直肠癌、TNBC 等II 期临床中展现良好疗效。海外拓展：关注新临床节奏，看好超级重磅潜力依沃西单抗的HARMONi 和HARMONi-3 两个海外III 期正在推进，其中后者适用人群从非鳞癌扩大至全人群，针对PD-L1 强阳性患者的HARMONi-7研究将在25 年初启动，我们看好本品在肺癌领域的成功潜力。此外，考虑到其他IO 联用抗血管生成的探索和依沃西单抗在部分瘤种的早期临床疗效，我们预计其适应症拓展将在海外展开，助推本品成为全球重磅级别品种。其他管线：商业化稳步推进，下一代肿瘤治疗全面布局成熟管线进入兑现阶段：1）卡度尼利单抗迎来新适应症获批浪潮，近日成功纳入医保，同时胃癌领域受益ODAC 会议决议，出海潜力再现；2）伴随伊努西单抗的获批，非肿瘤药物等有望在未来3 年陆续上市。我们与市场观点不同之处市场在部分同机理竞品BD 后仍在观望依沃西单抗的海外潜力，我们认为HARMONi-2 研究的数据较为严密，其在海外临床复制国内成功的可能性较大，并有望伴随着其他适应症临床的后续落地，持续推动海外潜力兑现。盈利预测与估值由于国谈和非肿瘤类药物获批节奏影响，我们下调2024/2025/2026 年公司营收至23.12/33.42/54.09 亿（较原值下调13.0/20.8/14.0%），归母净利润为(4.34)/0.71/6.48 亿元，对应EPS 为(0.48)/0.08/0.72 元。将依沃西单抗海外市场的潜在长期现金流纳入测算，我们将DCF 终值现值由360 亿提升至652 亿元，给予公司目标市值845 亿元（WACC 9.4%，永续增长率3.0%），对应目标价100.45 港币（前值60.73 港币）。风险提示：临床试验进度及存在不确定性；产品商业化风险；海外临床试验存在失败的风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492163114"}

康方生物(9926.HK)：临床突破不断 全球潜力彰显

精彩评论

康方生物(9926.HK)：临床突破不断全球潜力彰显